Alacrita

Executive Summary

Alacrita is a UK-based life science consulting firm founded in 2015, offering strategic and execution support to biotech, pharma, and investor clients. Leveraging a global network of over 350 industry specialists, the company provides tailored expertise across therapeutic areas and product modalities, from preclinical planning to commercialization. Its integrated services cover product development, enterprise strategy, and business development, positioning it as a versatile partner for companies navigating complex drug development landscapes. As a private consulting firm, Alacrita's growth is driven by expanding client engagements and deepening its specialist network. The company benefits from increasing demand for outsourced expertise in the biopharma sector, particularly as small biotechs and large pharma alike seek to optimize R&D efficiency. Key drivers include new client wins, geographic expansion, and the addition of senior consultants. While Alacrita does not have traditional drug development catalysts, its success is tied to the broader industry trend of external innovation and flexible staffing.

Upcoming Catalysts (preview)

• TBDMajor Pharmaceutical Partnership Win50% success
• Q3 2026Expansion into US Market via New Office60% success
• Q4 2026Launch of Specialized Consulting Practice in Cell & Gene Therapy70% success